Risk prediction of prognosis for severe community-acquired pneumonia complicated by chronic obstructive pulmonary disease

doi:10.3877/cma.j.issn.1674-6902.2025.03.026

Abstract

Ning You, Wei Qin, Bin Xu, Yilian Peng, Xiaoyu Yang. Risk prediction of prognosis for severe community-acquired pneumonia complicated by chronic obstructive pulmonary disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(03): 479-482.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.03.026

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I03/479

Figures/Tables 4

References 30

1	Liu YN，Zhang YF，Xu Q，et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020：a national surveillance study［J］. Lancet Microbe，2023，4（5）：e330-e339.
2	Qin T，Zhou H，Ren H，et al. Incidence，etiology，and environmental risk factors of community-acquired pneumonia requiring hospitalization in China：A 3-year，prospective，age-stratified，multicenter case-control study［J］. Open Forum Infect Dis，2021，8（11）：ofab499.
3	Wise RA，Bafadhel M，Crim C，et al. Discordant diagnostic criteria for pneumonia in COPD trials：a review［J］. Eur Respir Rev，2021，30（162）：210124.
4	de Miguel-Diez J，Lopez-Herranz M，Hernandez-Barrera V，et al.Community-acquired pneumonia among patients with COPD in spain from 2016 to 2019. Cohort study assessing sex differences in the incidence and outcomes using hospital discharge data［J］. J Clin Med，2021，10（21）：4889.
5	Sheikh D，Tripathi N，Chandler TR，et al. Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non-SARS-CoV-2 community-acquired pneumonia ［J］. Respir Med，2022，191：106714.
6	刘熙，李琦. 我国成人社区获得性肺炎诊疗现状及思考［J/CD］. 中华肺部疾病杂志（电子版），2021，14（3）：387-389.
7	Agustí A，Celli BR，Criner GJ，et al. Global initiative for chronic obstructive lung disease 2023 report：GOLD executive summary［J］.Am J Respir Crit Care Med，2023，207（7）：819-837.
8	Bonnesen B，Baunbæk Egelund G，Vestergaard Jensen A，et al. Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia ［J］. Infect Dis（Lond），2019，51（5）：340-347.
9	Dai RX，Kong QH，Mao B，et al. The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease：a retrospective cohort study［J］. BMC Pulm Med，2018，18（1）：12.
10	Shin B，Kim SH，Yong SJ，et al. Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia［J］. Chron Respir Dis，2019，16：1479972318809480.
11	Bradley J，Sbaih N，Chandler TR，et al. Pneumonia severity index and CURB-65 score are good predictors of mortality in hospitalized patients with SARS-CoV-2 community-acquired pneumonia ［J］.Chest，2022，161（4）：927-936.
12	Kılınç Toker A，Çelik Ī，Toker Ī，et al. Quick COVID-19 severity index，CURB-65 and quick SOFA scores comparison in predicting mortality and risk factors of COVID-19 patients［J］. Arch Iran Med，2022，25（7）：443-449.
13	Glöckner V，Pletz MW，Rohde G，et al. Early post-discharge mortality in CAP：frequency，risk factors and a prediction tool［J］. Eur J Clin Microbiol Infect Dis，2022，41（4）：621-630.
14	吕伟伟，丁玲，王言理. COPD 并发重症肺炎患者预后影响因素分析［J/CD］. 中华肺部疾病杂志（电子版），2022，15（03）：349-351.
15	Restrepo MI，Mortensen EM，Waterer GW，et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia［J］. Eur Respir J，2009，33（1）：153-159.
16	李坤徉，张莉. 慢性阻塞性肺疾病急性加重并发糖尿病的危险因素分析［J/CD］. 中华临床医师杂志（电子版），2022，16（6）：493-500.
17	王小川，王汉超，姚宇，等. 慢性阻塞性肺疾病急性加重期合并2 型糖尿病患者的临床特征和危险因素分析与治疗［J］. 中国临床药理学与治疗学，2024，29（4）：392-400.
18	商焕霞，郭立娟，张罗元，等. AECOPD 患者肺功能指标与血清白介素相关因子水平的关系［J/CD］. 中华肺部疾病杂志（电子版），2024，17（1）：123-126.
19	Ernst P，Saad N，Suissa S. Inhaled corticosteroids in COPD：the clinical evidence ［J］. Eur Respir J，2015，45（2）：525-37.
20	齐奇，叶蕊，赵立. 降血糖药物对慢性阻塞性肺疾病潜在作用的研究现状［J］. 中国临床药理学杂志，2022，38（8）：859-863.
21	Chan L E，Casiraghi E，Laraway B，et al. Metformin is associated with reduced COVID-19 severity in patients with prediabetes［J］.medRxiv，2022，doi：10.1101/2022.08.29.22279355.
22	钟明媚，丁震，李秀，等. 血清血管生成素-2 与老年人社区获得性肺炎严重程度的相关性研究［J］. 中华老年医学杂志，2022，41（1）：26-29.
23	Karakioulaki M，Stolz D. Biomarkers and clinical scoring systems in community-acquired pneumonia ［J］. Ann Thorac Med，2019，14（3）：165-72.
24	Luo B，Sun M，Huo X，et al. Two new inflammatory markers related to the CURB-65 score for disease severity in patients with community-acquired pneumonia：The hypersensitive C-reactive protein to albumin ratio and fibrinogen to albumin ratio［J］. Open Life Sci，2021，16（1）：84-91.
25	钟伯年，彭明，钟秀平. 血浆纤维蛋白原在社区获得性肺炎临床治疗中的应用价值［J］. 临床肺科杂志，2019，24（3）：412-5.
26	王子铭，屈越，黄梅，等. 重症成人社区获得性肺炎列线图预测模型的构建和验证［J］. 中华危重病急救医学，2022，34（9）：935-940.
27	Agustí A，Celli BR，Criner GJ，et al. Global initiative for chronic obstructive lung disease 2023 report：GOLD executive summary ［J］.Eur Respir J，2023，61（4）：2300239.
28	戚国庆，刘伟. 血清MMP-9、KL-6 在不同时期COPD 患者中的表达及临床意义［J］. 标记免疫分析与临床，2020，27（7）：1125-1129.
29	Torres A，Chalmers JD，Dela Cruz CS，et al. Challenges in severe community-acquired pneumonia：a point-of-view review ［J］.Intensive Care Med，2019，45（2）：159-171.
30	Florin TA，Ambroggio L，Lorenz D，et al. Development and internal validation of a prediction model to risk stratify children with suspected community-acquired pneumonia ［J］. Clin Infect Dis，2021，73（9）：e2713-e2721.

临床资料	生存者（n=66）	死亡者（n=43）	t/χ²	P 值
GOLD 分级 [M(P₂₅,P₇₅)]	3.0 (2.0,3.0)	3.0 (2.5,3.0)	1203.0	0.145
糖尿病 [n(%)]	9 (13.64)	8 (18.60)	0.49	0.485
慢性肾病 [n(%)]	6 (9.09)	5 (11.63)	0.18	0.750
休克 [n(%)]	19 (28.79)	16 (37.21)	0.85	0.357
呼吸衰竭 [n(%)]	35 (53.03)	20 (46.51)	0.44	0.506
收缩压 [mmHg, M(P₂₅,P₇₅)]	110 (100,119)	109 (101,120)	1385.0	0.835
舒张压 [mmHg, M(P₂₅,P₇₅)]	68 (59,79)	68 (59,80)	1445.5	0.872
纤维蛋白原 [g/L, M(P₂₅,P₇₅)]	3.70 (3.06,4.64)	4.34 (2.77,5.53)	1255.5	0.312
IL-6 [pg/ml, M(P₂₅,P₇₅)]	47.33 (10.54,163.13)	35.68 (12.61,99.14)	1522.0	0.525
BUN [(mmol/L, M(P₂₅,P₇₅)]	7.77 (5.74,13.43)	8.22 (5.28,11.18)	1507.5	0.585
CRP [mg/L, M(P₂₅,P₇₅)]	43.21 (23.02,123.96)	52.69 (14.14,109.81)	1499.0	0.622
乳酸 [(mmol/L, M(P₂₅,P₇₅)]	1.3 (1.0,1.8)	1.3 (0.9,1.6)	1448.5	0.857
白细胞计数 [10⁹/L, M(P₂₅,P₇₅)]	8.88 (6.73,13.63)	12.15 (7.21,14.59)	1178.5	0.137
疾病严重程度评分 [M(P₂₅,P₇₅)]	2.0 (1.0,2.0)	2.0 (1.0,3.0)	1280.5	0.366

临床资料	生存者（n=66）	死亡者（n=43）	t/χ²	P 值
GOLD 分级 [M(P₂₅,P₇₅)]	3.0 (2.0,3.0)	3.0 (2.5,3.0)	1203.0	0.145
糖尿病 [n(%)]	9 (13.64)	8 (18.60)	0.49	0.485
慢性肾病 [n(%)]	6 (9.09)	5 (11.63)	0.18	0.750
休克 [n(%)]	19 (28.79)	16 (37.21)	0.85	0.357
呼吸衰竭 [n(%)]	35 (53.03)	20 (46.51)	0.44	0.506
收缩压 [mmHg, M(P₂₅,P₇₅)]	110 (100,119)	109 (101,120)	1385.0	0.835
舒张压 [mmHg, M(P₂₅,P₇₅)]	68 (59,79)	68 (59,80)	1445.5	0.872
纤维蛋白原 [g/L, M(P₂₅,P₇₅)]	3.70 (3.06,4.64)	4.34 (2.77,5.53)	1255.5	0.312
IL-6 [pg/ml, M(P₂₅,P₇₅)]	47.33 (10.54,163.13)	35.68 (12.61,99.14)	1522.0	0.525
BUN [(mmol/L, M(P₂₅,P₇₅)]	7.77 (5.74,13.43)	8.22 (5.28,11.18)	1507.5	0.585
CRP [mg/L, M(P₂₅,P₇₅)]	43.21 (23.02,123.96)	52.69 (14.14,109.81)	1499.0	0.622
乳酸 [(mmol/L, M(P₂₅,P₇₅)]	1.3 (1.0,1.8)	1.3 (0.9,1.6)	1448.5	0.857
白细胞计数 [10⁹/L, M(P₂₅,P₇₅)]	8.88 (6.73,13.63)	12.15 (7.21,14.59)	1178.5	0.137
疾病严重程度评分 [M(P₂₅,P₇₅)]	2.0 (1.0,2.0)	2.0 (1.0,3.0)	1280.5	0.366

影响因素	单变量分析		多变量分析
影响因素	OR(95%CI)	P 值	OR(95%CI)	P 值
年龄	1.022 (1.005~1.039)	0.012	1.025 (1.003~1.047)	0.025
GOLD 分级	17.37 (4.231~71.320)	0.000	18.13 (5.169~76.378)	0.000
糖尿病	1.618 (1.052~2.489)	0.028	1.974 (1.156~3.371)	0.013
慢性肾病	2.378 (1.242~4.554)	0.009	2.708 (1.182~6.204)	0.019
休克	8.287 (2.168~31.684)	0.002	8.978 (3.972~29.48)	0.014
呼吸衰竭	7.225 (1.533~34.042)	0.012	7.537 (1.487~30.764)	0.016
收缩压（mmHg）	0.979 (0.973~0.985)	0.000	0.980 (0.972~0.988)	0.000
纤维蛋白原（g/L）	1.375 (1.250~1.512)	0.000	1.305 (1.153~1.476)	0.000
IL-6（pg/ml）	1.013 (1.010~1.015)	0.000	1.012 (1.009~1.014)	0.000
BUN（mmol/L）	1.081 (1.054~1.109)	0.000	1.058 (1.024~1.094)	0.014

影响因素	单变量分析		多变量分析
影响因素	OR(95%CI)	P 值	OR(95%CI)	P 值
年龄	1.022 (1.005~1.039)	0.012	1.025 (1.003~1.047)	0.025
GOLD 分级	17.37 (4.231~71.320)	0.000	18.13 (5.169~76.378)	0.000
糖尿病	1.618 (1.052~2.489)	0.028	1.974 (1.156~3.371)	0.013
慢性肾病	2.378 (1.242~4.554)	0.009	2.708 (1.182~6.204)	0.019
休克	8.287 (2.168~31.684)	0.002	8.978 (3.972~29.48)	0.014
呼吸衰竭	7.225 (1.533~34.042)	0.012	7.537 (1.487~30.764)	0.016
收缩压（mmHg）	0.979 (0.973~0.985)	0.000	0.980 (0.972~0.988)	0.000
纤维蛋白原（g/L）	1.375 (1.250~1.512)	0.000	1.305 (1.153~1.476)	0.000
IL-6（pg/ml）	1.013 (1.010~1.015)	0.000	1.012 (1.009~1.014)	0.000
BUN（mmol/L）	1.081 (1.054~1.109)	0.000	1.058 (1.024~1.094)	0.014

Please choose a citation manager

Content to export

Risk prediction of prognosis for severe community-acquired pneumonia complicated by chronic obstructive pulmonary disease

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 30

Related Articles 0

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export

Risk prediction of prognosis for severe community-acquired pneumonia complicated by chronic obstructive pulmonary disease

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 4

References 30

Related Articles 0

Recommended Articles

Metrics

Comments